Factor VII - redOrbit

News - Factor VII

CSL Behring Commences Phase I Study With rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors

2012-03-30 10:22:19

KING OF PRUSSIA, Pa., March 30, 2012 /PRNewswire/ -- CSL Behring announced today the first in human dosing of recombinant fusion protein

First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII

2012-02-24 13:00:00

VIENNA, Feb.

Inspiration Biopharmaceuticals Highlights Positive Data on its Recombinant Factor IX for People with Hemophilia B Who Have Undergone Major Surgical Procedures

2012-02-22 07:30:00

ROME, Feb. 22, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc.

CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors

2012-02-16 07:00:00

KING OF PRUSSIA, Pa., Feb.

PROLOR Biotech Announces Positive Preclinical Results from Comparative Study of its Long-Acting Clotting Factor VIIa

2012-02-14 06:30:00

NES-ZIONA, Israel, Feb. 14, 2012 /PRNewswire/ -- PROLOR Biotech, Inc.

More News (123 articles) »